News
(2)April 2026
Tvardi Therapeutics (TVRD) Annual Report Highlights Clinical Pipeline and Cash Burn
# 🧾 What This Document Is This is an Annual Report to Shareholders (ARS), a comprehensive yearly update that public companies must send to their investors. Think of it as a "state of the union" for the business, covering strategy, financial performance, and future plans. It's more detailed than a q
March 2026
Tvardi Therapeutics, Inc. — 8-K Filing
# 🧾 What This Document Is This is an 8-K filing, which is a report of major events that shareholders should know about. Specifically, this filing includes an **Exhibit 99.1**, which is a press release from Tvardi Therapeutics. It combines their **fourth quarter and full-year 2025 financial results*
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.